Holen Sie sich die Stockscreener-App
3.10
4.03%
0.12
Handel nachbörslich:
3.10
Agenus Inc Aktie (AGEN) Neueste Nachrichten
Agenus Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Immuno-oncology initiatives expand to address unmet cancer needs, Agenus asserts - Traders Union
Agenus receives $20M payment from Zydus collaboration By Investing.com - Investing.com Canada
Agenus receives $20M payment under Zydus Life Sciences collaboration - MSN
Agenus receives $20M payment from Zydus collaboration - Investing.com Nigeria
Agenus (AGEN) Secures $20M Milestone Payment from Zydus Partners - GuruFocus
Agenus Triggers First $20 Million Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - marketscreener.com
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - Business Wire
Agenus warns most metastatic colorectal cancer cases are MSS, calling for innovation to tackle resistance - Traders Union
Benny Johnson is Now The Executive Medical Director at Agenus - Oncodaily
Aug Patterns: Should I invest in Agenus Inc before earningsBuy Signal & Smart Money Movement Tracker - baoquankhu1.vn
How Agenus Inc. stock compares to market leaders2025 Bull vs Bear & Long-Term Safe Return Strategies - Naître et grandir
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update - Business Wire
Agenus (AGEN) to Release Earnings on Tuesday - MarketBeat
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
AGEN Technical Analysis & Stock Price Forecast - Intellectia AI
Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC - Finviz
Stock-paid salary boosts Armen’s Agenus (AGEN) share holdings - Stock Titan
How resilient is Agenus Inc. stock in market downturnsJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - mfd.ru
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL - BioSpace
CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type - GlobeNewswire Inc.
AGEN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Why Agenus Inc. stock could outperform in 2025Weekly Risk Report & Real-Time Volume Trigger Notifications - mfd.ru
Why is Agenus Inc. stock going downJuly 2025 Reactions & Smart Allocation Stock Tips - mfd.ru
Response to the Misleading Open Letter by “Diaspora Leaders”: Statement by Dr. Garo Armen, Founder of the Children of Armenia Fund (COAF) - MassisPost
The Old System Failed Patients. Change Must Go Further and Faster – Garo Armen - Oncodaily
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors - BioSpace
Aug Sentiment: Why is Agenus Inc stock going downQuarterly Trade Summary & Community Supported Trade Ideas - baoquankhu1.vn
Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch - MarketBeat
Agenus (AGEN) Q2 2025 Earnings Call Transcript - The Globe and Mail
Colorectal Cancer is Moving in the Wrong Direction – Agenus - Oncodaily
Agenus Strengthens Medical Affairs Infrastructure to Support Growing Authorized Access to Botensilimab–Balstilimab - Oncodaily
Agenus Lands $141M Zydus Partnership to Power BOT+BAL and U.S. Manufacturing Expansion - Oncodaily
Expansion of Global Medical Affairs to Support BOT+BAL Access – Agenus - Oncodaily
Agenus expands medical affairs to support early access to cancer therapy By Investing.com - Investing.com Nigeria
Looking Into Agenus Inc's Recent Short Interest - Benzinga
Agenus expands medical affairs to support early access to cancer therapy - Investing.com
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab - Business Wire
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation - Citeline News & Insights
Agenus Announces First Stakeholder Webcast of 2026 Focused on BOT+BAL Program - Intellectia AI
Agenus to Host First 2026 Stakeholder Webcast - The AI Journal
Agenus signals expanded access and 2026 plans - Traders Union
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):